Literature DB >> 14630924

Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9.

Yasunari Takada1, Bharat B Aggarwal.   

Abstract

Flavopiridol, a synthetic flavone closely related to a compound originally isolated from the stem bark of the native Indian plant Dysoxylum binectariferum, has been found to inhibit cyclin-dependent kinases, induce apoptosis, suppress inflammation, and modulate the immune response. Because several genes in which expression is altered by flavopiridol are regulated by NF-kappaB, we propose that this flavone must affect the activation of NF-kappaB. For this report, we investigated the effect of flavopiridol on NF-kappaB activation by various carcinogens and inflammatory agents. Flavopiridol suppressed tumor necrosis factor (TNF)-activation of NF-kappaB in a dose- and time-dependent manner in several cell types, with optimum inhibition occurring upon treatment of cells with 100 nm flavopiridol for 6 h. This effect was mediated through inhibition of IkappaBalpha kinase, phosphorylation, ubiquitination, and degradation of IkappaBalpha (an inhibitor of NF-kappaB), and suppression of phosphorylation, acylation, and nuclear translocation of the p65 subunit of NF-kappaB. Besides TNF, flavopiridol also suppressed NF-kappaB activated by a carcinogen (cigarette smoke condensate), tumor promoters (phorbol myristate acetate and okadaic acid), and an inflammatory agent (H2O2). TNF-induced NF-kappaB-dependent reporter gene transcription was also suppressed by this flavone. NF-kappaB reporter activity induced by TNF receptor 1, TNF receptor-associated death domain, TNF receptor-associated factor-2, NF-kappaB-inducing kinase, and IkappaBalpha kinase, were all blocked by flavopiridol but not that activated by p65. Furthermore, flavopiridol suppressed TNF-induced activation of Akt. Flavopiridol also inhibited the expression of the TNF-induced NF-kappaB-regulated gene products cyclin D1, cyclooxygenase-2, and matrix metalloproteinase-9. Overall, our results indicated that flavopiridol inhibits activation of NF-kappaB and NF-kappaB-regulated gene expression, which may explain the ability of flavopiridol to suppress inflammation, modulate the immune response, and regulate cell growth.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14630924     DOI: 10.1074/jbc.M304546200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.

Authors:  Beata Holkova; Steven Grant
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

Review 2.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

3.  Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

Authors:  Asaka Kondo; Taishi Yamashita; Hideto Tamura; Wanhong Zhao; Takashi Tsuji; Masumi Shimizu; Eiji Shinya; Hidemi Takahashi; Koji Tamada; Lieping Chen; Kazuo Dan; Kiyoyuki Ogata
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

4.  Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells.

Authors:  Yasunari Takada; Michael Andreeff; Bharat B Aggarwal
Journal:  Blood       Date:  2005-04-05       Impact factor: 22.113

5.  Expression of NF-kappaB in hRPE cells stimulated by PDTC and IL-1beta.

Authors:  Jun Hu; Guigang Li; Jianbin Chen; Hong Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

6.  Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).

Authors:  Kami Maddocks; Lai Wei; Darlene Rozewski; Yao Jiang; Yuan Zhao; Mikhil Adusumilli; William E Pierceall; Camille Doykin; Michael H Cardone; Jeffrey A Jones; Joseph Flynn; Leslie A Andritsos; Michael R Grever; John C Byrd; Amy J Johnson; Mitch A Phelps; Kristie A Blum
Journal:  Am J Hematol       Date:  2015-02-25       Impact factor: 10.047

7.  [Aspects of traditional Indian medicine (Ayurveda) in urology].

Authors:  J Mani; S Kumar; G J Dobos; A Haferkamp
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

8.  Enhancement of radiation effects by flavopiridol in uterine cervix cancer cells.

Authors:  Suzy Kim; Hong-Gyun Wu; Jin Hee Shin; Hye Jin Park; In Ah Kim; Il Han Kim
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

9.  Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.

Authors:  Velasco Cimica; Melissa E Smith; Zhikai Zhang; Deepti Mathur; Sridhar Mani; Ganjam V Kalpana
Journal:  BMC Cancer       Date:  2010-11-19       Impact factor: 4.430

Review 10.  Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer.

Authors:  Sander W Tas; Margriet J B M Vervoordeldonk; Paul P Tak
Journal:  Curr Gene Ther       Date:  2009-06       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.